As the White House nears a decision on its Section 232 pharmaceutical investigation, which will determine whether imports of pharmaceuticals and their components pose a threat to U.S. national security, that conclusion should already be clear as it relates to generic medicines. President Trump should treat these more affordable and critical medicines as the national […]
Author Archives: Kathleen Jaeger
Kathleen Jaeger is the spokesperson for the Indian Pharmaceutical Alliance. She wrote this for InsideSources.com.
